A substantial decrease in the proportion of non-myeloid (CD11b−) cell accumulation (containing mostly tumor cells as confirmed by cytology) after MIS416 vaccination, indicated an anti-tumor effect by MIS416 (Fig. 3a). Here, ITGAM is linked to neoplasm.